HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Regulatory News Round Up: NSAIDs During Pregnancy, Estragole Excipients, ePIs

Executive Summary

CMDh receives applications to change how NSAIDs are recommended for use during pregnancy; HMPC warns against use of estragole-containing excipients in herbals; EMA adopts new EU common standard for electronic product information on medicines marketed within the region.

You may also be interested in...



EU Bitter Fennel Oil Monograph May Be Withdrawn Due To Estragole Safety Concerns

The European Medicines Agency’s Committee on Herbal Medicinal Products (HMPC) says the EU herbal monograph for bitter fennel oil “cannot be supported anymore” because of new data on the genotoxicity and carcinogenicity of estragole.

UK Consumers Want Greener Manufacturing, Recyclable Packaging And Better Information

Commitments to environmentally sustainable production processes and recyclable packaging for OTC products are increasingly important to UK consumers, according to a recent PAGB survey. Consumers would also like more information about how products should be recycled and are open to the idea of electronic product information.

Haleon, Teva And PAGB Join UK Sustainable Medicines Partnership

Haleon, Teva and UK consumer healthcare industry association, PAGB, are among 42 members of the Sustainable Medicines Partnership, which “aims to build science-based, scalable, sustainable solutions to help reduce the waste of medicines and the waste from medicines.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel